Treatment of Small Bowel Neuroendocrine Tumor (NETS): A Single Center's Experience Abstract #385

Introduction: Neuroendocrine tumors (NETS) of the gastrointestinal tract are rare, slow-growing neoplasms. Long-term management of these tumors varies among centers.
Aim(s): To determine if long-term multidisciplinary management at a single center maximizes survival, records from NET patients were reviewed and survival rates were calculated and compared to historical controls.
Materials and methods: The charts of 401 consecutive patients with well-differentiated, small bowel NETS, treated at a collaborative clinic were reviewed. Information relating to the extent of disease and all tumor-related surgeries were collected from the patient records. Kaplan-Meier survival curves were generated, and 5-year, 10-year, and median survival rates were calculated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
Keywords: survival

To read results and conclusion, please login ...

Further abstracts you may be interested in

#594 Neurokinin A Levels Predict Survival in Patients with Well-Differentiated Small Bowel Neuroendocrine Tumors
Introduction: Recent European investigations demonstrated that persistently elevated (> 50 pg/ml) plasma neurokinin A (NKA) levels are associated with poor short-term survival in patients with midgut neuroendocrine tumors (NETS).
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Eugene Woltering
#386 A Prospective Evaluation of the Effects of Chronic Proton Pump Inhibitor Use on Plasma Biomarker Levels in Humans
Introduction: Proton pump inhibitors (PPIs) are used primarily to treat gastroesophageal reflux disease. PPI-induced achlorhydria increases circulating gastrin and chromogranin A (CGA). CGA is a widely used biomarker for the diagnosis and follow-up for gut-based neuroendocrine tumors (NETs). PPI-induced increases in CGA or gastrin may falsely suggest the presence of a NET when none exists. Pancreastatin, a fragment of CGA, is also commonly used to diagnose and follow NETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Eugene Woltering
#1064 Development of Effective Prophylaxis Against Intraoperative Carcinoid Crisis
Introduction: Patients with foregut and midgut neuroendocrine tumors (NETs) can experience life-threatening carcinoid crises during anesthesia. The prophylactic use of a pre-, intra- and post-operative high dose continuous octreotide infusion was evaluated for its ability to prevent carcinoid crises during cytoreductive surgeries.
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Eugene Woltering
Keywords: carcinoid crisis
#599 Rectal Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: The rectum is the third most common location for gastrointestinal carcinoids after small bowel and colon. Due to their rarity, the characteristics and behavior of this unusual malignancy remain unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Cai Jianqiang
Authors: Du F, Chi Y H B L, Zhao H, Wang J W, ...
#300 Association Between Time to Disease Progression Endpoints and Overall Survival in Patients with Neuroendocrine Tumors
Introduction: While the association between time to disease progression (TDP) and overall survival (OS) has been examined in a variety of cancers, it has not been assessed in trials of neuroendocrine tumors (NETs).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Thomas E Delea
Authors: Delea T E, Rotter J, Wang X, ...